KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBITDA Margin (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of EBITDA Margin readings, the most recent being 34568.22% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 3458963.0% to 34568.22% in Q4 2025 year-over-year; TTM through Dec 2025 was 56.07%, a 7589.0% increase, with the full-year FY2025 number at 30.06%, up 4987.0% from a year prior.
  • EBITDA Margin hit 34568.22% in Q4 2025 for Biocryst Pharmaceuticals, up from 7.78% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 34568.22% in Q4 2025 to a low of 336.35% in Q1 2021.
  • Median EBITDA Margin over the past 5 years was 48.89% (2022), compared with a mean of 1661.68%.
  • Biggest five-year swings in EBITDA Margin: crashed -5221bps in 2022 and later surged 3458963bps in 2025.
  • Biocryst Pharmaceuticals' EBITDA Margin stood at 37.57% in 2021, then plummeted by -139bps to 89.78% in 2022, then grew by 27bps to 65.52% in 2023, then skyrocketed by 67bps to 21.41% in 2024, then skyrocketed by 161526bps to 34568.22% in 2025.
  • The last three reported values for EBITDA Margin were 34568.22% (Q4 2025), 7.78% (Q3 2025), and 3.43% (Q2 2025) per Business Quant data.